## Deepak Voora

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7188563/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cost-effectiveness of <i>CYP2C19</i> -guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes. European Heart Journal Quality of Care & Clinical Outcomes, 2023, 9, 249-257.	4.0	3
2	Aspirin effects on platelet gene expression are associated with a paradoxical, increase in platelet function. British Journal of Clinical Pharmacology, 2022, 88, 2074-2083.	2.4	4
3	Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma. Value in Health, 2022, 25, 582-594.	0.3	6
4	<i>SLCO1B1*5</i> Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care. Clinical Pharmacology and Therapeutics, 2022, 111, 1075-1083.	4.7	10
5	The Clinical Pharmacogenetics Implementation Consortium Guideline for <i>SLCO1B1</i> , <i>ABCG2</i> , and <i>CYP2C9</i> genotypes and Statinâ€Associated Musculoskeletal Symptoms. Clinical Pharmacology and Therapeutics, 2022, 111, 1007-1021.	4.7	120
6	Risk factors, transcriptomics, and outcomes of myocardial injury following lower extremity revascularization. Scientific Reports, 2022, 12, 6718.	3.3	1
7	A precision medicine approach to stress testing using metabolomics and microribonucleic acids. Personalized Medicine, 2022, 19, 287-297.	1.5	1
8	OUP accepted manuscript. Cardiovascular Research, 2022, , .	3.8	1
9	Associations of a polygenic risk score with coronary artery disease phenotypes in the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. American Heart Journal, 2022, 252, 12-15.	2.7	3
10	Gene Expression Profiles of Treatment Response and <scp>Nonâ€Response</scp> in Children With Juvenile Dermatomyositis. ACR Open Rheumatology, 2022, 4, 671-681.	2.1	4
11	Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder. JAMA - Journal of the American Medical Association, 2022, 328, 151.	7.4	55
12	Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 1480-1488.e14.	4.4	53
13	Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans. Journal of Thrombosis and Thrombolysis, 2021, 51, 249-259.	2.1	6
14	North Carolina's multi-institutional pharmacogenomics efforts with the North Carolina Precision Health Collaborative. Pharmacogenomics, 2021, 22, 73-80.	1.3	1
15	Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network. Genetics in Medicine, 2021, 23, 1185-1191.	2.4	17
16	Delivery of Pharmacogenetic Testing with or without Medication Therapy Management in a Community Pharmacy Setting. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 785-796.	0.7	0
17	Platelets amplify endotheliopathy in COVID-19. Science Advances, 2021, 7, eabh2434.	10.3	78
18	United States Emergency Department Use of Medications with Pharmacogenetic Recommendations. Western Journal of Emergency Medicine, 2021, 22, 1347-1354.	1.1	1

#	Article	lF	CITATIONS
19	Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. Value in Health, 2020, 23, 61-73.	0.3	30
20	Longitudinal RNA-Seq Analysis of the Repeatability of Gene Expression and Splicing in Human Platelets Identifies a Platelet <i>SELP</i> Splice QTL. Circulation Research, 2020, 126, 501-516.	4.5	39
21	Influence of Sex on Platelet Reactivity in Response to Aspirin. Journal of the American Heart Association, 2020, 9, e014726.	3.7	21
22	Identifying End Users' Preferences about Structuring Pharmacogenetic Test Orders in an Electronic Health Record System. Journal of Molecular Diagnostics, 2020, 22, 1264-1271.	2.8	2
23	Understanding the state of pharmacogenomic testing for thiopurine methyltransferase within a large health system. Pharmacogenomics, 2020, 21, 411-418.	1.3	3
24	Modeling statin myopathy in a human skeletal muscle microphysiological system. PLoS ONE, 2020, 15, e0242422.	2.5	4
25	Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets, 2019, 30, 579-588.	2.3	4
26	Pilot study of myocardial ischemia-induced metabolomic changes in emergency department patients undergoing stress testing. PLoS ONE, 2019, 14, e0211762.	2.5	7
27	Genetic influences on aspirin response in patients undergoing percutaneous coronary intervention. Cardiovascular Research, 2019, 115, 1452-1453.	3.8	1
28	Future directions in pharmacogenomics discovery in cardiovascular disease. Pharmacogenomics, 2018, 19, 375-377.	1.3	0
29	Cardiovascular Pharmacogenetics. , 2018, , 291-307.		0
30	Unraveling the Genetic Basis of Recurrent Venous Thromboembolism. Circulation Genomic and Precision Medicine, 2018, 11, .	3.6	1
31	Multisite Investigation of Outcomes WithÂImplementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 181-191.	2.9	213
32	Effects of Delivering <i>SLCO1B1</i> Pharmacogenetic Information in Randomized Trial and Observational Settings. Circulation Genomic and Precision Medicine, 2018, 11, e002228.	3.6	40
33	Peripheral blood gene expression signatures which reflect smoking and aspirin exposure are associated with cardiovascular events. BMC Medical Genomics, 2018, 11, 1.	1.5	12
34	An age- and sex-specific gene expression score is associated with revascularization and coronary artery disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. American Heart Journal, 2017, 184, 133-140.	2.7	13
35	Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting. Pharmacogenomics, 2017, 18, 327-335.	1.3	14
36	Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease. Clinical Chemistry, 2017. 63, 177-185.	3.2	9

#	Article	IF	CITATIONS
37	The need for sex-specific precision biomarkers for antiplatelet therapies. Future Cardiology, 2017, 13, 419-422.	1.2	1
38	The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement From the American Heart Association. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	21
39	Transcription Factor RUNX1 Regulates Platelet <i>PCTP</i> (Phosphatidylcholine Transfer Protein): Implications for Cardiovascular Events. Circulation, 2017, 136, 927-939.	1.6	18
40	An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System. PLoS ONE, 2017, 12, e0187809.	2.5	10
41	Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer. EBioMedicine, 2016, 11, 157-164.	6.1	19
42	Rationale and design of the <i>SLCO1B1</i> genotype guided statin therapy trial. Pharmacogenomics, 2016, 17, 1873-1880.	1.3	4
43	Pharmacometabolomics Meets Genetics. Journal of the American College of Cardiology, 2016, 67, 1211-1213.	2.8	11
44	Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmacogenomics and Personalized Medicine, 2015, 8, 43.	0.7	27
45	Gene Expression Profiles Link Respiratory Viral Infection, Platelet Response to Aspirin, and Acute Myocardial Infarction. PLoS ONE, 2015, 10, e0132259.	2.5	23
46	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. European Heart Journal, 2015, 36, 1901-1912.	2.2	107
47	Gene Expression Signatures and the Spectrum of Coronary Artery Disease. Journal of Cardiovascular Translational Research, 2015, 8, 339-352.	2.4	9
48	<i>SLCO1B1</i> genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. Pharmacogenomics, 2015, 16, 449-458.	1.3	17
49	Module-Based Association Analysis for Omics Data with Network Structure. PLoS ONE, 2015, 10, e0122309.	2.5	5
50	Genetically Guided Statin Therapy on Statin Perceptions, Adherence, and Cholesterol Lowering: A Pilot Implementation Study in Primary Care Patients. Journal of Personalized Medicine, 2014, 4, 147-162.	2.5	31
51	A Freeze on Tailored Antiplatelet Therapy?. Circulation, 2014, 129, 2088-2090.	1.6	1
52	Platelet RNA as a novel biomarker for the response to antiplatelet therapy. Future Cardiology, 2014, 10, 9-12.	1.2	5
53	Expression Quantitative Trait Locus Analysis Identifies Novel Genes for Statin Myopathy. Circulation: Cardiovascular Genetics, 2014, 7, 220-221.	5.1	0
54	Preoperative CYP2D6 metabolism-dependent Î <sup>2</sup> -blocker use and mortality after coronary artery bypass grafting surgery. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1368-1375.e3.	0.8	12

#	Article	IF	CITATIONS
55	PREDICTing the Era of Personalized Medicine. Science Translational Medicine, 2014, 6, .	12.4	1
56	The Last Line of Defense Against Atherosclerosis. Science Translational Medicine, 2014, 6, .	12.4	1
57	A Powerful (Re)Purpose for Genome-Wide Association Studies. Science Translational Medicine, 2014, 6,	12.4	0
58	Aspirin Exposure Reveals Novel Genes Associated With Platelet Function and Cardiovascular Events. Journal of the American College of Cardiology, 2013, 62, 1267-1276.	2.8	65
59	A Host-Based RT-PCR Gene Expression Signature to Identify Acute Respiratory Viral Infection. Science Translational Medicine, 2013, 5, 203ra126.	12.4	133
60	A Transcriptomics-Informed Genetic Association Study Identifies <b> <i>RHOA</i> </b> in Simvastatin-Induced Low-Density Lipoprotein Cholesterol Lowering. Circulation: Cardiovascular Genetics, 2013, 6, 137-138.	5.1	0
61	Building the evidentiary framework for pharmacogenetic testing: is it time to move beyond randomized controlled trials?. Personalized Medicine, 2013, 10, 1-3.	1.5	2
62	Delivering pharmacogenetic testing in a primary care setting. Pharmacogenomics and Personalized Medicine, 2013, 6, 105.	0.7	37
63	Hemostasis and Thrombosis. , 2013, , 602-611.		1
64	A Liquid Solution for Solid Tumors. Science Translational Medicine, 2013, 5, .	12.4	1
65	A miR-aculous Advance for a Rare Heart Disorder. Science Translational Medicine, 2013, 5, .	12.4	0
66	XiAP-ping Castration-Resistant Prostate Cancer. Science Translational Medicine, 2013, 5, .	12.4	0
67	Drugs and Bugs. Science Translational Medicine, 2013, 5, .	12.4	0
68	Drug-Induced Aches and Pains. Science Translational Medicine, 2013, 5, .	12.4	1
69	Silencing the Sounds of Hypertrophic Cardiomyopathy. Science Translational Medicine, 2013, 5, .	12.4	0
70	Clinical Application of Cardiovascular Pharmacogenetics. Journal of the American College of Cardiology, 2012, 60, 9-20.	2.8	65
71	Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy. Journal of Thrombosis and Thrombolysis, 2012, 33, 246-257.	2.1	23
72	The pharmacogenetics of antiplatelet agents: towards personalized therapy?. Nature Reviews Cardiology, 2011, 8, 560-571.	13.7	38

#	Article	IF	CITATIONS
73	Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. American Heart Journal, 2011, 162, 166-172.e1.	2.7	38
74	Institutional Profile: A hub for bench-to-bedside pharmacogenomic-based research. Pharmacogenomics, 2011, 12, 1095-1098.	1.3	7
75	Prevalence and Clinical Characteristics Associated With Left Atrial Appendage Thrombus in Fully Anticoagulated Patients Undergoing Catheterâ€Directed Atrial Fibrillation Ablation. Journal of Cardiovascular Electrophysiology, 2010, 21, 849-852.	1.7	63
76	The Long and Winding Road to Warfarin Pharmacogenetic Testing. Journal of the American College of Cardiology, 2010, 55, 2813-2815.	2.8	40
77	Pharmacogenetics of the response to statins. Current Cardiovascular Risk Reports, 2009, 3, 434-440.	2.0	4
78	The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects. Journal of the American College of Cardiology, 2009, 54, 1609-1616.	2.8	452
79	Pharmacogenetic Predictors of Statin-Mediated Low-Density Lipoprotein Cholesterol Reduction and Dose Response. Circulation: Cardiovascular Genetics, 2008, 1, 100-106.	5.1	80
80	Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood, 2007, 110, 1511-1515.	1.4	164
81	Is primary care ready for pharmacogenetics?. Pharmacogenomics, 2006, 7, 1-3.	1.3	6
82	Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thrombosis and Haemostasis, 2005, 93, 700-705.	3.4	176
83	The pharmacogenetics of coumarin therapy. Pharmacogenomics, 2005, 6, 503-513.	1.3	86
84	Use of pharmacogenetics to guide warfarin therapy. Drugs of Today, 2004, 40, 247.	2.4	7
85	Mesenteric Vein Thrombosis Associated with Intravaginal Contraceptives: A Case Report and Review of the Literature. Journal of Thrombosis and Thrombolysis, 2003, 15, 105-108.	2.1	13